Cargando…

Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase

Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isofo...

Descripción completa

Detalles Bibliográficos
Autores principales: Battisti, Umberto Maria, Gao, Chunixa, Akladios, Fady, Kim, Woonghee, Yang, Hong, Bayram, Cemil, Bolat, Ismail, Kiliclioglu, Metin, Yuksel, Nursena, Tozlu, Ozlem Ozdemir, Zhang, Cheng, Sebhaoui, Jihad, Iqbal, Shazia, Shoaie, Saeed, Hacimuftuoglu, Ahmet, Yildirim, Serkan, Turkez, Hasan, Uhlen, Mathias, Boren, Jan, Mardinoglu, Adil, Grøtli, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919951/
https://www.ncbi.nlm.nih.gov/pubmed/36771285
http://dx.doi.org/10.3390/nu15030577
_version_ 1784886950384107520
author Battisti, Umberto Maria
Gao, Chunixa
Akladios, Fady
Kim, Woonghee
Yang, Hong
Bayram, Cemil
Bolat, Ismail
Kiliclioglu, Metin
Yuksel, Nursena
Tozlu, Ozlem Ozdemir
Zhang, Cheng
Sebhaoui, Jihad
Iqbal, Shazia
Shoaie, Saeed
Hacimuftuoglu, Ahmet
Yildirim, Serkan
Turkez, Hasan
Uhlen, Mathias
Boren, Jan
Mardinoglu, Adil
Grøtli, Morten
author_facet Battisti, Umberto Maria
Gao, Chunixa
Akladios, Fady
Kim, Woonghee
Yang, Hong
Bayram, Cemil
Bolat, Ismail
Kiliclioglu, Metin
Yuksel, Nursena
Tozlu, Ozlem Ozdemir
Zhang, Cheng
Sebhaoui, Jihad
Iqbal, Shazia
Shoaie, Saeed
Hacimuftuoglu, Ahmet
Yildirim, Serkan
Turkez, Hasan
Uhlen, Mathias
Boren, Jan
Mardinoglu, Adil
Grøtli, Morten
author_sort Battisti, Umberto Maria
collection PubMed
description Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isoforms. In this work, we report that ellagic acid (EA) and its derivatives, present in numerous fruits and vegetables, can inhibit PKL potently and selectively. Several polyphenolic analogues of EA were synthesized and tested to identify the chemical features responsible for the desired activity. Molecular modelling studies suggested that this inhibition is related to the stabilization of the PKL inactive state. This unique inhibition mechanism could potentially herald the development of new therapeutics for NAFLD.
format Online
Article
Text
id pubmed-9919951
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99199512023-02-12 Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase Battisti, Umberto Maria Gao, Chunixa Akladios, Fady Kim, Woonghee Yang, Hong Bayram, Cemil Bolat, Ismail Kiliclioglu, Metin Yuksel, Nursena Tozlu, Ozlem Ozdemir Zhang, Cheng Sebhaoui, Jihad Iqbal, Shazia Shoaie, Saeed Hacimuftuoglu, Ahmet Yildirim, Serkan Turkez, Hasan Uhlen, Mathias Boren, Jan Mardinoglu, Adil Grøtli, Morten Nutrients Article Liver pyruvate kinase (PKL) has recently emerged as a new target for non-alcoholic fatty liver disease (NAFLD), and inhibitors of this enzyme could represent a new therapeutic option. However, this breakthrough is complicated by selectivity issues since pyruvate kinase exists in four different isoforms. In this work, we report that ellagic acid (EA) and its derivatives, present in numerous fruits and vegetables, can inhibit PKL potently and selectively. Several polyphenolic analogues of EA were synthesized and tested to identify the chemical features responsible for the desired activity. Molecular modelling studies suggested that this inhibition is related to the stabilization of the PKL inactive state. This unique inhibition mechanism could potentially herald the development of new therapeutics for NAFLD. MDPI 2023-01-22 /pmc/articles/PMC9919951/ /pubmed/36771285 http://dx.doi.org/10.3390/nu15030577 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Battisti, Umberto Maria
Gao, Chunixa
Akladios, Fady
Kim, Woonghee
Yang, Hong
Bayram, Cemil
Bolat, Ismail
Kiliclioglu, Metin
Yuksel, Nursena
Tozlu, Ozlem Ozdemir
Zhang, Cheng
Sebhaoui, Jihad
Iqbal, Shazia
Shoaie, Saeed
Hacimuftuoglu, Ahmet
Yildirim, Serkan
Turkez, Hasan
Uhlen, Mathias
Boren, Jan
Mardinoglu, Adil
Grøtli, Morten
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title_full Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title_fullStr Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title_full_unstemmed Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title_short Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
title_sort ellagic acid and its metabolites as potent and selective allosteric inhibitors of liver pyruvate kinase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919951/
https://www.ncbi.nlm.nih.gov/pubmed/36771285
http://dx.doi.org/10.3390/nu15030577
work_keys_str_mv AT battistiumbertomaria ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT gaochunixa ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT akladiosfady ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT kimwoonghee ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT yanghong ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT bayramcemil ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT bolatismail ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT kiliclioglumetin ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT yukselnursena ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT tozluozlemozdemir ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT zhangcheng ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT sebhaouijihad ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT iqbalshazia ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT shoaiesaeed ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT hacimuftuogluahmet ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT yildirimserkan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT turkezhasan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT uhlenmathias ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT borenjan ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT mardinogluadil ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase
AT grøtlimorten ellagicacidanditsmetabolitesaspotentandselectiveallostericinhibitorsofliverpyruvatekinase